Update: Recent FDA approval of Aduhelm (aducanumab) for treatment of Alzheimer’s disease
Recently the FDA approved the use of Aduhelm (aducanumab) for the treatment of Alzheimer's disease. Aducanumab is the first approved therapy to work directly on amyloid, one of the two proteins that builds up in the brain to cause Alzheimer's disease. We are also aware that there are questions around the approval of this drug, and will provide more information about this in the future.
In the meantime, we are building out the processes to determine who might benefit from this therapy and how it may be administered.
Patients: If you would like to learn more about aducanumab, please call 617-667-4074, and choose option #5. Please leave your name, email address and phone number on this voicemail. You will be contacted once we have more information to share.
Healthcare providers: If you have patients who are interested in learning more about aducanumab, please email MemoryA2Z@bidmc.harvard.edu. (Alternatively, you can have your patients contact us directly by the phone.
We plan on keeping our community informed through email and this website as we take these next steps in treating Alzheimer's disease together.